Jeremy Skillington of Poolbeg Pharma: AI partner has completed build & optimisation of its RSV human challenge data
Episode 762, Jun 27, 2022, 06:23 AM
Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses how their Artificial Intelligence partner OneThree Biotech, Inc., has completed the build and optimisation of a tailored AI model of Poolbeg's Respiratory Syncytial Virus human challenge data and can now commence its analysis, with results expected in Q4 2022.
Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses how their Artificial Intelligence partner OneThree Biotech, Inc., has completed the build and optimisation of a tailored AI model of Poolbeg's Respiratory Syncytial Virus human challenge data and can now commence its analysis, with results expected in Q4 2022.
Highlights:
• Build and optimisation phase of AI model to identify RSV drug targets and treatments completed - results expected in Q4 2022
• Model is uniquely tailored to use Poolbeg's human challenge trial data of RSV
• The Directors believe this is the first time that AI analysis has been used to identify new drug targets and treatments for RSV using human challenge trial data
• Process will identify novel drug targets and treatments quicker and in a more cost-efficient manner than previously possible
To read full RNS click HERE